Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia - Business Wire

Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia  Business Wire

U.S. FDA grants Priority Review for REVLIMID® (lenalidomide) in combination with rituximab (R²) for previously treated follicular and marginal zone lymphoma.



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more